-transparent.png){kind=logo}
The lysozyme (muramidase) activity was measured in the sera of 84 dogs with neoplastic disease. Neoplasms included 32 lymphomas, 13 primary bone neoplasms, 5 melanomas, 5 thyroid neoplasms, 9 soft tissue sarcomas, 5 mast cell sarcomas, and 15 carcinomas. The sera from 21 healthy dogs served as control. Dogs with neoplastic disease had significantly (P less than 0.005) higher serum lysozyme activity than did the healthy controls. For lymphosarcoma, dogs with clinical signs of systemic disease had significantly higher serum lysozyme activity than did dogs without clinical signs. For bone neoplasms, dogs with metastatic disease had higher serum lysozyme activity than did dogs without metastasis. Increased lysozyme activity may be a useful marker of macrophage-mediated host responses to neoplasms in dogs.
B F Feldman, and
B R Madewell, and
R B Miller
March 1986,
Veterinary research communications,
B F Feldman, and
B R Madewell, and
R B Miller
January 1971,
Texas reports on biology and medicine,
B F Feldman, and
B R Madewell, and
R B Miller
January 1989,
Advances in peritoneal dialysis. Conference on Peritoneal Dialysis,
B F Feldman, and
B R Madewell, and
R B Miller
November 1982,
American journal of clinical pathology,
B F Feldman, and
B R Madewell, and
R B Miller
February 1995,
Nihon rinsho. Japanese journal of clinical medicine,
B F Feldman, and
B R Madewell, and
R B Miller
November 2004,
Nihon rinsho. Japanese journal of clinical medicine,
B F Feldman, and
B R Madewell, and
R B Miller
August 1999,
Nihon rinsho. Japanese journal of clinical medicine,
B F Feldman, and
B R Madewell, and
R B Miller
May 1973,
American journal of veterinary research,
B F Feldman, and
B R Madewell, and
R B Miller
January 1987,
Indian journal of ophthalmology,
B F Feldman, and
B R Madewell, and
R B Miller
August 1978,
American journal of veterinary research,
